Short Interest in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Increases By 79.8%

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,097 shares, an increase of 79.8% from the February 12th total of 610 shares. Based on an average daily trading volume, of 1,575 shares, the short-interest ratio is currently 0.7 days. Currently, 0.7% of the shares of the company are sold short. Currently, 0.7% of the shares of the company are sold short. Based on an average daily trading volume, of 1,575 shares, the short-interest ratio is currently 0.7 days.

Amplify Weight Loss Drug & Treatment ETF Stock Down 0.5%

Shares of THNR stock opened at $24.30 on Friday. The firm has a 50 day moving average price of $25.90 and a two-hundred day moving average price of $24.84. The company has a market capitalization of $3.65 million, a PE ratio of 24.31 and a beta of 0.61. Amplify Weight Loss Drug & Treatment ETF has a 12-month low of $18.56 and a 12-month high of $27.28.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The company also recently announced an annual dividend, which was paid on Wednesday, December 31st. Stockholders of record on Tuesday, December 30th were paid a dividend of $0.4132 per share. The ex-dividend date was Tuesday, December 30th. This represents a dividend yield of 162.0%.

Institutional Trading of Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC raised its position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.